Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of the largest early stage financings in China biotech history.

Researchers from Sungkyunkwan University and Txinno Bioscience Inc. recently presented their work where they aimed to design, synthesize and evaluate ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitors containing a benzotriazole core and a sulfonimidamide Zn binder.

Shanghai Henlius Biotech Inc. has presented preclinical data on HLX-403, its novel anti-CDH17 antibody-drug conjugate (ADC), highlighting its potential for gastrointestinal cancers. A first-in-human trial is expected to commence in the third quarter of this year.

Researchers from the Sino-American Cancer Foundation and Taipei Medical University have developed a novel nanobody-based CAR T-cell platform directed against C-type lectin-like molecule-1 (CLL-1) for the possible treatment of acute myeloid leukemia (AML).

Liminatus Pharma Inc. has announced plans to conduct a phase I trial of IBA-101, a next-generation CD47-blockade antibody designed to work alongside PD-1/PD-L1 checkpoint inhibitors across a range of solid tumors.

Glioblastoma multiforme (GBM) is an aggressive and highly invasive intracranial tumor arising from the malignant transformation of brain and spinal cord cells. To date, surgery followed by adjuvant chemotherapy is the standard therapy for treating GBM, where temozolomide is the only first-line FDA-approved drug for GBM treatment. The aim of this study from Shenzhen University was to test the effect of a novel chloroethyl nitrosourea analog, HJ-03, in the treatment of GBM, which might overcome temozolomide resistance.